Main > > >HEART FAILURE. *
Acutely Decompensated Severe Chronic Heart Failure. Treat.: Levosimendan.
(*) Company : Orion Corp.
Patent : Expired
TradeMark: Simdax
Web-Site : www.simdax.com
UpDate: 2019. 04.08.
And Arrhytmia Management System.
USA Launch Date: 2019. 06.10.
(*) Company : Zoll Medical.
TradeMark: ZOLL µCor™
UpDate: 2019. 11.09.
Cardio.>AHF (Advanced Heart Failure). Treat.: LVAD. (Left Ventricular Assist Device).
Used for Patients needing Short- or Long-term Mechanical Circulatory Support (e.g., Bridge To Transplant (BTT) or Myocardial Recovery, or Destination Therapy (DT)).
with Magnetic Levitation Technology.
EU Approval Date : 2015. 10.>
>Implanted through Open Heart Surgery
USA Approval Date: 2017. 08.28.>
>Implanted through Open Heart Surgery
USA Approval Date: 2020. 01.07.>
>Implanted through Incision in Chest
Wall
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2020. 01.08.
Cardio.>CHF (Chronic Heart Failure). Hospitalization Prognosis Blood Immuno- Assay.
(*) Company; Patent; TradeMark & Web-
Site Available on Request.
UpDate: 2019. 12.20.
Chronic Heart Failure (CHF). TREAT.: CCM (Cardiac Contractility Modulation) Therapy
BR Approval Date : 2015. 08.31.
CN Approval Date : 2017. 12.18.
EU Launch Date : ?
RU Approval Date : 2016. 01.26.
USA Approval Date: 2019. 03.21.
USA Approval Date: 2021. 01.20>
>Use of MRI
(*) Company; Patents; TradeMark & Web-
Sites Available on Request.
UpDate: 2021. 02.07.
Cardio.>CHF (Chronic Heart Failure). TREAT.: Ivabradine.
INDICATION: Reduce the Risk of Death and
Hospitalization.
With Reduced Ejection Fraction.
CA Approval Date: 2017. 01.10.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2019. 04.04.
Cardio.>CHF (Chronic Heart Failure) TREAT.: Sacubitril/Valsartan Tablets.
Angiotensin Receptor-Neprilysin Inhibi-
tor.
INDICATION: Reduce the Risk of Death and
Hospitalization
With Reduced Ejection Fraction.
EU Approval Date : 2015. 11.29.
USA Approval Date: 2015. 07.07.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2019. 04.03.
Cardio.>CHF (Chronic Heart Failure). TREAT.: Shunt. Left Atrial Pressure (LAP) Reduction.
EU Approval Date: 2020. 03.05.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2020. 03.09.
Cardio.>CHF (Chronic Heart Failure). TREAT.: TransCatheter Ventricular Enhan- cement System.
Less Invasive Procedure.
EU CE Mark Date : 2016. 06.27.
EU CE Mark Extension till: 2024. 05.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2020. 02.02.
Cardio.>DiUretics. SpironoLactone Oral Suspension. 25 mg/5 mL.
Antagonist of Aldosterone.
- Indications:
treatment of NYHA Class III-IV heart
failure and reduced ejection fraction
to increase survival, manage edema,
and to reduce the need for
hospitalization for heart failure; use
as an add-on therapy for the treatment
of hypertension, to lower blood
pressure; the management of edema in
adult cirrhotic patients when edema is
not responsive to fluid and sodium
restrictions.
USA Approval Date: 2017. 08.07.
USA Launch Date : 2017. 10.30.
(*) Company; Patent; TradeMark & Web-
Site Available on Request.
UpDate: 2019. 04.01
Cardio.>Heart Failure (HF). Functional Mitral Regurgitation (FMR). TREAT.: Right Heart Transcatheter Mitral Valve repair (TMVr) Device.
Acute Hemodynamic Efficacy.
FMR results from "Dilation of Left>
>Ventricle" (main pumping chamber of the
heart). As left ventricle increases in
size, the mitral valve also expands.
This "dimensional" increase leads to
MR. which reduces amount of blood flow
out of left ventricle. FMR associated
with "reduced functional capacity"
Implantable Device>Proximal Anchor>
>& Distal Anchor. Utilizing proximity of
coronary sinus to mitral annulus
apparatus, , the device is designed to
reduce mitral annulus dilatation upon
deployment, thereby reducing FMR,
Rapidly delivered via the venous
vasculature, ..
Mitral Regurgitation (MR) grades 2+,3+>
>&4+
Non-Surgical Treatment
Percutaneous Mitral Annuloplasty therapy
Reduce Mitral Annulus Dilatation.
AU Approval Date: 2020. 09.02.
EU Approval Date: 2011. 09.29.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2020. 09.03.
Cardio.>Heart Failure (HF). Lung Fluid Management Device.
USA Launch Date: 2019. 09.17.
(*) Company; Patent; TradeMark & Web-
Site Available on Request.
UpDate: 2019. 10.27.
Cardio.>Heart Failure (HF). reduced Ejection Fraction (rEF). Treat.: Dapagliflozin.
USA Approval Date: 2020. 05.05.
(*) Company; Patents; TradeMark &
Web-Site Available on Request.
UpDate: 2020. 08.24.
Cardio.>Heart Failure (HF). Symptomatic. Treat.: Enalapril Maleate Oral Solution.
USA Approval Date: 2013. 08.14.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2019. 07.14.
Cardio.>Heart Failure (HF). Systolic. Reduction of Signs & Symptoms: Lisino- pril Oral Solution.
USA Approval Date: 2016. 07.29.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2019. 07.14.
Cardio.>Heart Failure (HF). Treat.: Cardiac Resynchronization Therapy (CRT).
Wireless Cardiac Pacing System.
Wireless Endocardial Pacing System.
Wireless Heart Stimulation.
EU Approval Date: 2015. 10.05.
(*) Company; Patents; Technology Trade
Mark & Web-Site Available on Request
UpDate: 2019. 09.01.
Cardio.>Heart Failure (HF). Treat.: Im- plantable NeuroModulation Device.
EU Approval Date : 2014. 09.29.
USA Approval Date: 2019. 08.16.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2021. 02.06.
Cardio.>Heart Failure (HF). Treat.: Iso- sorbide Dinitrate/Hydralazine.HCl.
(in Black Patients)
USA Approval Date: 2005. 06.23.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2019. 03.28.
Cardio.>Heart Failure (HF). WireLess Monitor.
USA Approval Date: 2014. 05.28.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2019. 03.05.
Cardio.>Heart Failure (HF). With Preser- ved or Mid-Range Ejection Fraction (HFpEF or HFmrEF) (Previously Called Diastolic HF). Treat.: InterAtrial Shunt Device. First Transcatheter Device.
EU Approval Date: 2016. 05.12.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2019. 09.22.
Chronic Heart Failure (CHF). Treat.:
Carvedilol Tablets
Initial U.S. Approval: 1995.
(*) Company : GSK
Patent : Expired
TradeMark: Coreg
UpDate: 2019. 03.27.
Chronic Heart Failure (CHF). Treat.:
Carvedilol. Brand.
Company : GSK
Patent : Expired
TradeMark: Coreg
UpDate: 2019. 04.21.
Chronic Heart Failure (CHF). Treat.:
Carvedilol Phosphate ER Capsules. Brand.
Initial U.S. Approval: 1995.
(*) Company : GSK.
Patent : Expired
TradeMark: Coreg CR
UpDate: 2019. 03.28.
Chronic Heart Failure (CHF). Treat.:
Carvedilol Phosphate ER Capsules. Gene-
ric.
USA Tentative Approval Date: 2017. 12.08
(*) Company: Impax Laboratories Inc.
UpDate: 2019. 03.28.
Class III–IV Heart Failure and Reduced Ejection Fraction to Increase Survival, Manage Edema, and to Reduce the Need for Hospitalization: Spironolactone Tablet, Film Coated.
(*) Company : Pfizer.
Patent : Expired
TradeMark: ALDACTONE
UpDate: 2019. 04.08.
Diagnostics & Assessment. VITROS® Immunodiagnostic Products NT-proBNP II Assay.
EU Approval Date: 2019. 07.23.
(*) Company: Ortho Clinical Diagnostics.
UpDate: 2019. 08.26.
Left Ventricular Assist Device (LVAD)
with Full MagLev (TM) Flow Technology ..
EU Approval Date : 2015. 10.
USA Approval Date: 2017. 08.23.
(*) Company : Abbott.
Patent Assignee: Thoratec Corp.
TradeMark : HeartMate 3
UpDate: 2019. 03.07.
Symptomatic. with Reduced Ejection Fraction (HFrEF) After an Acute Myocardial Infarction (AMI).
Survival Improvement: Eplerenone Ta-
blets. Generic.
Mechanism: Aldosterone AntAgonist.
(*) Company: Greenstone LLC.
UpDate: 2019. 02.18.Heart Failure (HF). Lung Fluid Manage-
ment Device.
USA Launch Date: 2019. 09.17.
(*) Company; Patent; TradeMark & Web-
Site Available on Request.
UpDate: 2019. 10.27.
TREAT.: Atrial Flow Regulator Device.
EU Approval Date: 2019. 09.06.
(*) Company : Occlutech AG.
UpDate: 2019. 10.27.
>HEART FAILURE. *'s products
This section has no products